公开(公告)号：US10736972B2

公开(公告)日：2020-08-11

申请号：US15573855

申请日：2016-05-26

Applicant: Memorial Sloan Kettering Cancer Center ,  Cornell University

Inventor： Michelle S. Bradbury ,  Ulrich Wiesner ,  Michael Overholtzer ,  Howard Scher ,  Kai Ma

IPC: A61K47/69 ,  A61K47/60 ,  A61K38/22

Abstract: Described herein is a method of induced cell death via ferroptosis by nanoparticle ingestion. Moreover, the present disclosure describes the administration of high concentrations of ultrasmall nanoparticles at multiple times over the course of treatment in combination with a nutrient-depleted environment, thereby modulating cellular metabolic pathways to induce cell death by the mechanism ferroptosis. Ferroptosis involves iron, reactive oxygen species, and a synchronous mode of cell death execution.

公开(公告)号：US10111963B2

公开(公告)日：2018-10-30

申请号：US14722307

申请日：2015-05-27

Applicant: Memorial Sloan Kettering Cancer Center ,  Cornell University

Inventor： Barney Yoo ,  Michelle Bradbury ,  Ulrich Wiesner ,  Kai Ma

IPC: A61K9/00 ,  A61K47/48 ,  A61K31/506 ,  A61K31/5377 ,  A61K49/00 ,  A61K51/12 ,  A61K47/65 ,  A61K47/60 ,  A61K47/69

Abstract: Described herein are nanoparticle drug conjugates (NDCs), which, in certain embodiments, comprise a non-toxic, multi-modality, clinically proven silica-based nanoparticle platform with covalently attached drug molecules/moieties. The nanoparticle drug conjugates (NDCs) demonstrate imaging capability and targeting ligands which efficiently clear through the kidneys. Furthermore, the conjugates incorporate therapeutic agents for cancer detection, prevention, and/or treatment.

公开(公告)号：US11931425B2

公开(公告)日：2024-03-19

申请号：US17566015

申请日：2021-12-30

Applicant: Memorial Sloan Kettering Cancer Center ,  Cornell University

Inventor： Michelle S. Bradbury ,  Ulrich Wiesner ,  Michael Overholtzer ,  Howard Scher ,  Kai Ma

IPC: A61K47/69 ,  A61K38/22 ,  A61K47/60

CPC classification number: A61K47/6929 ,  A61K38/22 ,  A61K47/60 ,  A61K47/6923

Abstract: Described herein is a method of induced cell death via ferroptosis by nanoparticle ingestion. Moreover, the present disclosure describes the administration of high concentrations of ultrasmall nanoparticles at multiple times over the course of treatment in combination with a nutrient-depleted environment, thereby modulating cellular metabolic pathways to induce cell death by the mechanism ferroptosis. Ferroptosis involves iron, reactive oxygen species, and a synchronous mode of cell death execution.

公开(公告)号：US11559591B2

公开(公告)日：2023-01-24

申请号：US16616368

申请日：2018-05-17

Applicant: Memorial Sloan Kettering Cancer Center ,  Cornell University

Inventor： Michelle S. Bradbury ,  Feng Chen ,  Ulrich Wiesner ,  Kai Ma

IPC: A61K51/12 ,  A61P35/00 ,  A61K51/04 ,  A61K51/08 ,  A61K51/10 ,  A61K49/00 ,  B82Y5/00 ,  B82Y15/00

Abstract: Described herein are nanoprobes comprising ultrasmall aminated and cRGDY-conjugated nanoparticles labeled with Zirconium-89 (89Zr) and methods of their use. The provided compositions are renally clearable and possess suitable blood circulation half-time, high tumor active targeting capability, dominant renal clearance, low liver accumulation, and a high tumor-to-background ratio. The described nanoprobes exhibit great potential as “target-or-clear” tracers to human subjects for systemic targeted imaging (or treatment) of cancer.

公开(公告)号：US11246946B2

公开(公告)日：2022-02-15

申请号：US16902577

申请日：2020-06-16

Applicant: Memorial Sloan Kettering Cancer Center ,  Cornell University

Inventor： Michelle S. Bradbury ,  Ulrich Wiesner ,  Michael Overholtzer ,  Howard Scher ,  Kai Ma

IPC: A61K47/69 ,  A61K47/60 ,  A61K38/22

Abstract: Described herein is a method of induced cell death via ferroptosis by nanoparticle ingestion. Moreover, the present disclosure describes the administration of high concentrations of ultrasmall nanoparticles at multiple times over the course of treatment in combination with a nutrient-depleted environment, thereby modulating cellular metabolic pathways to induce cell death by the mechanism ferroptosis. Ferroptosis involves iron, reactive oxygen species, and a synchronous mode of cell death execution.

公开(公告)号：US10732115B2

公开(公告)日：2020-08-04

申请号：US14410223

申请日：2013-06-24

Applicant: Cornell University

Inventor： Ulrich Wiesner ,  Kai Ma

IPC: G01N21/64 ,  A61K9/51 ,  A61K49/00 ,  A61K47/69

Abstract: Mesoporous oxide nanoparticles, compositions comprising such nanoparticle, and methods of making and using such nanoparticles. The nanoparticles (e.g., compositions comprising the nanoparticles) have an average size of less than 15 nm and a narrow size distribution. The nanoparticles can be used in imaging applications and delivery of molecular cargo (e.g., a drug) to an individual.

公开(公告)号：US20190351077A1

公开(公告)日：2019-11-21

申请号：US16414874

申请日：2019-05-17

Applicant: Memorial Sloan Kettering Cancer Center ,  Cornell University

Inventor： Michelle S. Bradbury ,  Barney Yoo ,  Ulrich Wiesner ,  Peiming Chen ,  Kai Ma ,  Snehal G. Patel ,  Daniella Karassawa Zanoni

IPC: A61K49/00 ,  A61B5/00 ,  A61K9/00

Abstract: Described herein are cyclic peptides, nanoparticles bound with cyclic peptides, and methods for using said cyclic peptides and/or said nanoparticles bound with cyclic peptides for intraoperative nerve tissue imaging.

公开(公告)号：US20180133342A1

公开(公告)日：2018-05-17

申请号：US15564315

申请日：2016-04-07

Applicant: Memorial Sloan Kettering Cancer Center ,  Cornell University ,  The Curators of the University of Missouri

Inventor： Barney Yoo ,  Thomas P. Quinn ,  Michelle S. Bradbury ,  Ulrich Wiesner ,  Jason Lewis ,  Kai Ma ,  Feng Chen

IPC: A61K47/69 ,  C07K16/40 ,  A61K49/18 ,  A61K49/00 ,  A61K45/06 ,  A61K51/10 ,  A61K51/12

Abstract: Disclosed herein are nanoparticle immunoconjugates useful for therapeutics and/or diagnostics. The immunoconjugates have diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution). In certain embodiments, the conjugates are silica-based nanoparticles with single chain antibody fragments attached thereto.

公开(公告)号：US20250019249A1

公开(公告)日：2025-01-16

申请号：US18616147

申请日：2024-03-25

Applicant: CORNELL UNIVERSITY

Inventor： Melik Z. Turker ,  Thomas C. Gardinier, II ,  Ulrich B. Wiesner ,  Kai Ma

IPC: C01B33/12 ,  A61K9/51 ,  A61K33/00 ,  A61K49/00 ,  A61K51/12

Abstract: Silica nanorings, methods of making silica nanorings, and uses of silica nanorings. The silica nanorings may be PEGylated. The silica nanorings may be surface functionalized, which may be surface selective functionalization, with one or more polyethylene glycol (PEG) group(s), one or more display group(s), one or more functional group(s), or a combination thereof. The silica nanorings may have a size of 5 to 20 nm. The silica nanorings may be made using micelles. The absence or presence of the micelles during PEGylation and/or functionalization allows for surface selective functionalization. The silica nanorings may be used in various diagnostic and/or treatment methods.

公开(公告)号：US11660354B2

公开(公告)日：2023-05-30

申请号：US16463865

申请日：2017-11-29

Applicant: Memorial Sloan Kettering Cancer Center ,  Cornell University ,  The Curators of the University of Missouri

Inventor： Michelle S. Bradbury ,  Thomas P. Quinn ,  Barney Yoo ,  Wolfgang Weber ,  Karim Touijer ,  Howard Scher ,  Kai Ma ,  Ulrich Wiesner

IPC: A61K49/00 ,  A61K51/08 ,  A61K51/12 ,  C07K7/02 ,  C07K17/00 ,  G01N33/574

CPC classification number: A61K49/0067 ,  A61K49/0002 ,  A61K49/0056 ,  A61K51/08 ,  A61K51/088 ,  A61K51/1244 ,  C07K7/02 ,  C07K17/00 ,  G01N33/57434

Abstract: Described herein are novel conjugates containing an inhibitor (e.g., a PSMA inhibitor, e.g., a gastrin-releasing peptide receptor inhibitor) and metal chelator that are covalently attached to a macromolecule (e.g., a nanoparticle, a polymer, a protein). Such conjugates exhibit distinct properties over the free, unbound inhibitor/chelator construct.